These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34090364)

  • 21. Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells.
    Pfister NT; Fomin V; Regunath K; Zhou JY; Zhou W; Silwal-Pandit L; Freed-Pastor WA; Laptenko O; Neo SP; Bargonetti J; Hoque M; Tian B; Gunaratne J; Engebraaten O; Manley JL; Børresen-Dale AL; Neilsen PM; Prives C
    Genes Dev; 2015 Jun; 29(12):1298-315. PubMed ID: 26080815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.
    Berge EO; Huun J; Lillehaug JR; Lønning PE; Knappskog S
    Biochim Biophys Acta; 2013 Mar; 1830(3):2790-7. PubMed ID: 23246812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells.
    Roger L; Jullien L; Gire V; Roux P
    J Cell Sci; 2010 Apr; 123(Pt 8):1295-305. PubMed ID: 20332115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma.
    Ganci F; Pulito C; Valsoni S; Sacconi A; Turco C; Vahabi M; Manciocco V; Mazza EMC; Meens J; Karamboulas C; Nichols AC; Covello R; Pellini R; Spriano G; Sanguineti G; Muti P; Bicciato S; Ailles L; Strano S; Fontemaggi G; Blandino G
    Clin Cancer Res; 2020 Jun; 26(12):2956-2971. PubMed ID: 31969334
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulation of p53 protein expression in human breast cancer cell lines.
    Vojtĕsek B; Lane DP
    J Cell Sci; 1993 Jul; 105 ( Pt 3)():607-12. PubMed ID: 8408290
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
    Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
    Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genome-Wide Small RNA Sequencing Identifies MicroRNAs Deregulated in Non-Small Cell Lung Carcinoma Harboring Gain-of-Function Mutant p53.
    Datta A; Das P; Dey S; Ghuwalewala S; Ghatak D; Alam SK; Chatterjee R; Roychoudhury S
    Genes (Basel); 2019 Oct; 10(11):. PubMed ID: 31661871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of gene expression in U251 glioblastoma cells by binding of mutant p53 R273H to intronic and intergenic sequences.
    Brázdová M; Quante T; Tögel L; Walter K; Loscher C; Tichý V; Cincárová L; Deppert W; Tolstonog GV
    Nucleic Acids Res; 2009 Apr; 37(5):1486-500. PubMed ID: 19139068
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Coan M; Toso M; Cesaratto L; Rigo I; Borgna S; Dalla Pietà A; Zandonà L; Iuri L; Zucchetto A; Piazza C; Baldassarre G; Spizzo R; Nicoloso MS
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762037
    [No Abstract]   [Full Text] [Related]  

  • 30. Plakoglobin restores tumor suppressor activity of p53
    Alaee M; Nool K; Pasdar M
    Cancer Sci; 2018 Jun; 109(6):1876-1888. PubMed ID: 29660231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.
    Nenutil R; Smardova J; Pavlova S; Hanzelkova Z; Muller P; Fabian P; Hrstka R; Janotova P; Radina M; Lane DP; Coates PJ; Vojtesek B
    J Pathol; 2005 Nov; 207(3):251-9. PubMed ID: 16161005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p53-Dependent repression of focal adhesion kinase in response to estradiol in breast cancer cell-lines.
    Anaganti S; Fernández-Cuesta L; Langerød A; Hainaut P; Olivier M
    Cancer Lett; 2011 Jan; 300(2):215-24. PubMed ID: 21071137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.
    Mehta SA; Christopherson KW; Bhat-Nakshatri P; Goulet RJ; Broxmeyer HE; Kopelovich L; Nakshatri H
    Oncogene; 2007 May; 26(23):3329-37. PubMed ID: 17130833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression.
    Oshiro MM; Watts GS; Wozniak RJ; Junk DJ; Munoz-Rodriguez JL; Domann FE; Futscher BW
    Oncogene; 2003 Jun; 22(23):3624-34. PubMed ID: 12789271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p53 mutants induce transcription of NF-κB2 in H1299 cells through CBP and STAT binding on the NF-κB2 promoter and gain of function activity.
    Vaughan CA; Singh S; Windle B; Sankala HM; Graves PR; Andrew Yeudall W; Deb SP; Deb S
    Arch Biochem Biophys; 2012 Feb; 518(1):79-88. PubMed ID: 22198284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcom.
    King SI; Purdie CA; Bray SE; Quinlan PR; Jordan LB; Thompson AM; Meek DW
    Breast Cancer Res; 2012 Mar; 14(2):R40. PubMed ID: 22405092
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation.
    Kong LR; Ong RW; Tan TZ; Mohamed Salleh NAB; Thangavelu M; Chan JV; Koh LYJ; Periyasamy G; Lau JA; Le TBU; Wang L; Lee M; Kannan S; Verma CS; Lim CM; Chng WJ; Lane DP; Venkitaraman A; Hung HT; Cheok CF; Goh BC
    Nat Commun; 2020 Apr; 11(1):2086. PubMed ID: 32350249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer.
    Xiao G; Lundine D; Annor GK; Canar J; Ellison V; Polotskaia A; Donabedian PL; Reiner T; Khramtsova GF; Olopade OI; Mazo A; Bargonetti J
    Cancer Res; 2020 Feb; 80(3):394-405. PubMed ID: 31776133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PLA2G16 is a mutant p53/KLF5 transcriptional target and promotes glycolysis of pancreatic cancer.
    Xia W; Bai H; Deng Y; Yang Y
    J Cell Mol Med; 2020 Nov; 24(21):12642-12655. PubMed ID: 32985124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ChIP-on-chip analysis of in vivo mutant p53 binding to selected gene promoters.
    Dell'Orso S; Fontemaggi G; Stambolsky P; Goeman F; Voellenkle C; Levrero M; Strano S; Rotter V; Oren M; Blandino G
    OMICS; 2011 May; 15(5):305-12. PubMed ID: 21332394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.